Unusual 11 Mid-Day Movers 08/02: (GNK) (GMCR) (FSLR) Higher; (KCG) (MTG) (HALO) Lower
Tweet
Share
E-mail
Get Alerts KCG Hot Sheet
Join SI Premium – FREE
Knight Capital Group, Inc. (NYSE: KCG) 56.6% LOWER; falling lower after announcing glitches in its trading system Wednesday. Losses on a pretax basis are expected to be $440 million. For more, click here.
MGIC Investment (NYSE: MTG) 55.9% LOWER; reported Q2 EPS of ($1.36), $0.80 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $321.1 million versus the consensus estimate of $298.61 million.
Halozyme Therapeutics, Inc. (Nasdaq: HALO) 51.1% LOWER; announced that the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Baxter's (NYSE: BAX) HyQ Biologics License Application (BLA). The letter requested additional preclinical data to support the BLA.
Genco Shipping & Trading Ltd. (NYSE: GNK) 40.1% HIGHER; reported Q2 EPS of ($0.65), $0.01 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $62.9 million versus the consensus estimate of $66.04 million.
Green Mountain Coffee Roasters (Nasdaq: GMCR) 29.6% HIGHER; reported Q3 EPS of $0.52, $0.02 better than the analyst estimate of $0.50. Revenue for the quarter came in at $869.2 million versus the consensus estimate of $873.29 million. Sees Q4 2012 EPS of $0.45-$0.50, versus the consensus of $0.62 and revenue of $889.9-$925.5 million, versus the consensus of $952.2 million. Also sees FY2012 EPS of $2.21-$2.26, versus the consensus of $2.37 and revenue of $3.79-$3.84 billion, versus the consensus of $3.87 billion. Approved $500 million buyback plan.
Aeropostale, Inc. (NYSE: ARO) 32.2% LOWER; said Q2 comps were flat, with sales rising 4 percent to $485.3 million. Cut its Q2 EPS outlook on lower-than-expected sales and margin results.
AVEO Pharmaceuticals (Nasdaq: AVEO) 26.8% LOWER; reported Q2 EPS of ($0.68), $0.21 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $1.54 million. The pharma reaffirmed FY2012 guidance.
First Solar, Inc. (Nasdaq: FSLR) 26.0% HIGHER; reported Q2 EPS of $1.27, $0.36 better than the analyst estimate of $0.91. Revenue for the quarter came in at $957 million versus the consensus estimate of $817.59 million. Sees FY2012 EPS of $4.20-$4.70, versus prior guidance of $4.00-$4.50 and the consensus of $3.95. First Solar, Inc. sees FY2012 revenue of $3.6-$3.9 billion, versus prior guidance of $3.5-$3.8 billion and the consensus of $3.48 billion.
Staar Surgical Co (Nasdaq: STAA) 24.1% HIGHER; reported Q2 EPS of $0.03, $0.02 better than the analyst estimate of $0.01. Revenue for the quarter came in at $15.9 million versus the consensus estimate of $16.96 million.
United Online, Inc. (Nasdaq: UNTD) 22.4% HIGHER; reported Q2 EPS of $0.18, $0.05 better than the analyst estimate of $0.13. Revenue for the quarter came in at $231.9 million versus the consensus estimate of $231.99 million. Sees Q3 2012 revenue of $172-$178 million, versus the consensus of $175.25 million.
Anika Therapeutics, Inc. (Nasdaq: ANIK) 22.3% HIGHER; reported Q2 revs rose 22 percent to $19.6 million while net income jumped 61 percent to $3.7 million, or 26 cents per share.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
MGIC Investment (NYSE: MTG) 55.9% LOWER; reported Q2 EPS of ($1.36), $0.80 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $321.1 million versus the consensus estimate of $298.61 million.
Halozyme Therapeutics, Inc. (Nasdaq: HALO) 51.1% LOWER; announced that the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Baxter's (NYSE: BAX) HyQ Biologics License Application (BLA). The letter requested additional preclinical data to support the BLA.
Genco Shipping & Trading Ltd. (NYSE: GNK) 40.1% HIGHER; reported Q2 EPS of ($0.65), $0.01 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $62.9 million versus the consensus estimate of $66.04 million.
Green Mountain Coffee Roasters (Nasdaq: GMCR) 29.6% HIGHER; reported Q3 EPS of $0.52, $0.02 better than the analyst estimate of $0.50. Revenue for the quarter came in at $869.2 million versus the consensus estimate of $873.29 million. Sees Q4 2012 EPS of $0.45-$0.50, versus the consensus of $0.62 and revenue of $889.9-$925.5 million, versus the consensus of $952.2 million. Also sees FY2012 EPS of $2.21-$2.26, versus the consensus of $2.37 and revenue of $3.79-$3.84 billion, versus the consensus of $3.87 billion. Approved $500 million buyback plan.
Aeropostale, Inc. (NYSE: ARO) 32.2% LOWER; said Q2 comps were flat, with sales rising 4 percent to $485.3 million. Cut its Q2 EPS outlook on lower-than-expected sales and margin results.
AVEO Pharmaceuticals (Nasdaq: AVEO) 26.8% LOWER; reported Q2 EPS of ($0.68), $0.21 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $1.54 million. The pharma reaffirmed FY2012 guidance.
First Solar, Inc. (Nasdaq: FSLR) 26.0% HIGHER; reported Q2 EPS of $1.27, $0.36 better than the analyst estimate of $0.91. Revenue for the quarter came in at $957 million versus the consensus estimate of $817.59 million. Sees FY2012 EPS of $4.20-$4.70, versus prior guidance of $4.00-$4.50 and the consensus of $3.95. First Solar, Inc. sees FY2012 revenue of $3.6-$3.9 billion, versus prior guidance of $3.5-$3.8 billion and the consensus of $3.48 billion.
Staar Surgical Co (Nasdaq: STAA) 24.1% HIGHER; reported Q2 EPS of $0.03, $0.02 better than the analyst estimate of $0.01. Revenue for the quarter came in at $15.9 million versus the consensus estimate of $16.96 million.
United Online, Inc. (Nasdaq: UNTD) 22.4% HIGHER; reported Q2 EPS of $0.18, $0.05 better than the analyst estimate of $0.13. Revenue for the quarter came in at $231.9 million versus the consensus estimate of $231.99 million. Sees Q3 2012 revenue of $172-$178 million, versus the consensus of $175.25 million.
Anika Therapeutics, Inc. (Nasdaq: ANIK) 22.3% HIGHER; reported Q2 revs rose 22 percent to $19.6 million while net income jumped 61 percent to $3.7 million, or 26 cents per share.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- After-Hours Movers: AMAT, DLO, GLOB, YSS, ETON
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Unusual 11 Mid-Day MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
